Insulin Glargine

• A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults with Type 2 D… Pending
  2024-520068-32-00 Phase IV 2 countries Novo Nordisk A/S
• SGLT-2i, Heart, Improvement of Cardiovascular Autonomic Neuropathy Recruiting
  2025-521748-39-00 Phase IV 1 country Universita Cattolica Del Sacro Cuore
• Searching simple biomarkers to phenotype type 2 diabetic patients and personalize their treatment Recruiting
  2024-516542-19-00 Phase IV 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination wi… Ended
  2024-519945-31-00 Phase III 4 countries Novo Nordisk A/S
• REIMAGINE 3: A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in people with type 2 diabete… Ended
  2022-502679-43-00 Phase III 1 country Novo Nordisk A/S
• A Research Study to See How Switching from a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar … Ended
  2023-506084-34-00 Phase III 4 countries Novo Nordisk A/S
• A research study to see how well new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar… Ended
  2022-502484-38-00 Phase III 3 countries Novo Nordisk A/S
• The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the tr… Ended
  2022-500449-26-00 Phase IV 5 countries University Medical Center Utrecht
• A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine… Ended
  2024-510612-75-00 Phase III 7 countries Novo Nordisk A/S

Showing 1–9 of 9 trials